Group 1 - The average stock price of A-shares is 13.27 yuan, with 33 stocks priced below 2 yuan, the lowest being *ST Suwu at 1.01 yuan [1] - Among the low-priced stocks, 13 are ST stocks, accounting for 39.39% of the total [1] - The Shanghai Composite Index closed at 3825.76 points as of August 22 [1] Group 2 - The top gainers among low-priced stocks include *ST Suwu, Jinju Group, and *ST Xingguang, with increases of 5.21%, 1.82%, and 1.55% respectively [1] - The top decliners include *ST Gaohong, *ST Jinke, and Jiugang Hongxing, with decreases of 5.00%, 1.46%, and 1.14% respectively [1] - The trading volume and turnover rates vary significantly among low-priced stocks, with *ST Suwu having a turnover rate of 3.49% [1]

| 股票名称 | 监控开始日期 监控结束日期 异动开始日期 | | | --- | --- | --- | | *ST苏吴 | 2025-08-21 2025-09-03 未披露 | | | 600200 | | | | 赛诺医疗 | 2025-08-19 2025-09-01 2025-08-07 | | | 688108 | | | | 东芯股份 | 2025-08-18 2025-08-29 2025-07-07 | | | 688110 | | | | 赛诺医疗 | 2025-08-18 2025-08-29 2025-08-07 | | | 688108 | | | | 淳中科技 | 2025-08-15 2025-08-28 未披露 | | | 603516 | | | | 长城军工 | 2025-08-14 2025-08-27 2025-07-31 | | | 601606 | | | | 赛诺医疗 | 2025-08-14 2025-08-27 | 2025-08-07 | | 688108 | | | *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 ...

Group 1 - The company announced the resignation of Vice President and Chief Financial Officer Sun Xi due to work adjustments, effective from August 21, 2025 [2] - The board approved the proposal for the company's President Jiang Zhong to temporarily assume the duties of the Chief Financial Officer until a new appointment is made [2] - The company will promptly hire a new Chief Financial Officer and fulfill related disclosure obligations as per legal requirements [2] Group 2 - The company is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to a risk warning for potential delisting due to major violations [5][6] - The company received a notice from the CSRC on July 13, 2025, indicating that it had inflated revenue, costs, and profits in its annual reports from 2020 to 2023, with inflated revenues amounting to approximately 495.26 million yuan in 2020, 468.51 million yuan in 2021, 430.75 million yuan in 2022, and 376.66 million yuan in 2023 [7] - The company's stock price has been below 1 yuan for six consecutive trading days, which could lead to termination of listing if it remains below this threshold for 20 consecutive trading days [5][6]

Core Viewpoint - The company, Jiangsu Wuzhong Pharmaceutical Development Co., Ltd., is facing the risk of being delisted due to significant legal violations, as it has been under investigation by the China Securities Regulatory Commission (CSRC) for falsifying financial statements from 2020 to 2023 [1][2][3] Group 1: Investigation and Legal Proceedings - The company received a notice of investigation from the CSRC on February 26, 2025, regarding its subsidiaries' involvement in non-substantive trade activities that inflated revenue, costs, and profits [1][2] - The CSRC's preliminary findings indicate that the company inflated its reported revenue by 26.46%, 26.39%, 21.26%, and 16.82% for the years 2020 to 2023, respectively [1] - The inflated operating costs amounted to 480.68 million yuan, 448.24 million yuan, 410.82 million yuan, and 355.44 million yuan for the same years, representing 37.08%, 35.47%, 28.40%, and 20.95% of the reported costs [1] Group 2: Stock Performance and Risks - The company's stock has been under a warning for potential delisting since July 14, 2025, due to the ongoing investigation and the risk of significant legal violations [2] - The stock price has been below 1 yuan for six consecutive trading days, which could lead to termination of listing if it remains below this threshold for 20 consecutive trading days [2] - The company has experienced significant stock price volatility, and there are concerns about speculative trading, urging investors to make informed decisions [2][3]

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-089 江苏吴中医药发展股份有限公司关于公司股票 可能被实施重大违法强制退市的第七次风险提示公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 2025 年 7 月 13 日，公司收到中国证监会下发的《行政处罚事先告知书》（处 罚字〔2025〕58 号），认定公司子公司江苏吴中进出口有限公司、中吴贸易发 展(杭州)有限公司、江苏吴中海利国际贸易有限公司通过与浙江优诺德贸易有限 公司等多家关联公司开展无商业实质的贸易业务，虚增营业收入、营业成本和利 润。上述行为导致*ST 苏吴在 2020 年至 2023 年年度报告中分别虚增营业收入 49,526.32 万元、46,850.82 万元、43,074.52 万元、37,666.41 万元，占当期披 露营业收入的 26.46%、26.39%、21.26%、16.82%；分别虚增营业成本 48,068.05 万元、44,823.70 万元、41,082.09 万元、35,544.47 万元，占当期披露营业成 本的 3 ...

关于副总裁、财务总监辞职暨总裁代行财务总监职责的公告 证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-088 江苏吴中医药发展股份有限公司 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 二、关于总裁代行财务总监职责的情况 江苏吴中医药发展股份有限公司 董事会 2025 年 8 月 22 日 一、副总裁、财务总监离任情况 姓名 离任职务 离任时间 原定任期到 期日 离任原因 是否继续在上市 公司及其控股子 公司任职 具体职务 （如适用） 是否存在未 履行完毕的 公开承诺 孙曦 副总裁、财 务总监 2025 年 8 月 21 日 2027 年 3 月 22 日 工作调整 原因 是 不适用 不适用 江苏吴中医药发展股份有限公司（以下简称"公司"）董事会于 2025 年 8 月 21 日收到孙曦先生的书面辞职报告，因工作调整原因，孙曦先生辞去公司副 总裁、财务总监职务，辞职后公司将另有任用。孙曦先生的辞职报告自送达董事 会之日起生效。 为保障公司财务管理工作的顺利开展，经公司董事会审计委员会同意，公司 于 2025 ...

New Stock Offerings - Shenke Co., Ltd. (002633) has a tender offer period from July 29, 2025, to August 27, 2025[1] - Fushun Special Steel (600399) has a tender offer period from August 12, 2025, to September 10, 2025[1] - Changcheng Military Industry (601606) announced a significant event on August 14, 2025[1] Market Alerts - Dongxin Co., Ltd. (688110) reported severe abnormal fluctuations on August 16, 2025[1] - ST Suwu (600200) has an announcement dated August 21, 2025, regarding market conditions[1] - Yunnan Zhiye (002428) and other companies have recent announcements on August 21, 2025, indicating market activity[1] Financial Performance - ST Jiangsu (600021) reported significant fluctuations on August 20, 2025, with a notable announcement[1] - ST Huanrong (600421) has an announcement dated August 20, 2025, reflecting market conditions[1] - ST Jinhong (000669) reported on August 20, 2025, indicating financial performance concerns[1]

证券之星消息，8月21日化学制药板块较上一交易日上涨0.09%，*ST苏吴领涨。当日上证指数报收于 3771.1，上涨0.13%。深证成指报收于11919.76，下跌0.06%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600200 | *ST苏吴 | 0.96 | 5.49% | 43.67万 | | 4141.60万 | | 300705 | 九典制药 | 19.87 | 4.97% | 52.35万 | | 10.35 Z | | 300573 | 兴齐眼药 | 67.48 | 4.69% | 22.77万 | | 15.19 Z | | 688506 | 百利天恒 | 324.96 | 4.21% | 1.62万 | | 5.23亿 | | 002940 | 昂利康 | 51.36 | 3.86% | 15.16万 | | 7.69亿 | | 002020 | 京新药业 | 19.52 | 2.90% | 32.05万 | | 6.16 ...

导语 低价股扎堆房地产、建筑、化工等行业 市场行情火热之际，A股百元股、翻倍股阵营扩容，与之相对，低价股数量在大幅减少。 分行业和板块看，不足3元的低价股超九成来自主板，扎堆房地产、建筑、化工等行业。一些低价股存在被立案或遭行政处罚等情况，部分甚至站在退市 边缘。 随着市场行情走热，一些年初还在低价股队伍的公司，如今已全身而退，年内股价翻番。例如，*ST宇顺（002289.SZ）最新股价28.33元，较年初涨幅已 近700%。这些"翻身"的低价股，多有并购、"易主"等消息加持。 二级市场上，低价股凭借低估值优势，或因热门概念题材傍身，容易吸引资金"捡便宜"。中航证券首席策略分析师张郁峰告诉第一财经，低价股股价弹性 大，容易出现明显异动，如果搭上一些概念题材，在牛市阶段股价容易被快速拉高。"不过，目前来看，市场对于低价股的炒作较为冷静。"他说。 菲林格尔4月初的盘中股价创出阶段新低4.9元，但随着"易主"消息披露，公司股价进入上涨通道。 "3元股""5元股"较年初减两成 8月20日，A股三大指数集体收涨，其中，沪指报收3766.21点，涨幅1.04%，两市成交额继续站上2万亿元，当日达2.41万亿元。 随着沪指 ...

Core Viewpoint - The A-share market has seen a significant reduction in the number of low-priced stocks, with many companies previously classified as low-priced experiencing substantial price increases due to mergers and acquisitions or changes in ownership [1][2][3]. Group 1: Market Trends - As of August 20, the number of stocks priced below 3 yuan and 5 yuan has decreased by over 20% since the beginning of the year, with 153 stocks below 3 yuan and 544 stocks below 5 yuan [2][3]. - The low-priced stock index has shown a cumulative increase of 16.49% year-to-date, with a 6.2% increase in August alone [2]. - The recent market rally has allowed several stocks to rise significantly, with *ST Yushun's price increasing from 3.56 yuan at the beginning of the year to 28.33 yuan, marking a 695% increase [1][3]. Group 2: Industry Analysis - Low-priced stocks are predominantly found in the real estate, construction, and chemical industries, with over 90% of stocks priced below 3 yuan coming from the main board [7][8]. - The real estate sector has several stocks priced below 2 yuan, including *ST Jinke and Rongsheng Development [9]. Group 3: Company-Specific Developments - *ST Yushun announced plans to acquire 100% of three companies, which led to a significant price surge, with the stock experiencing 14 consecutive trading days of gains [4]. - Filinger's stock price increased after the announcement of a change in control, with the stock rising from a low of 4.9 yuan to a high of 23.35 yuan following the news [5][6]. Group 4: Investor Sentiment - Despite the potential for low-priced stocks to attract investment due to their low valuations, current market sentiment towards these stocks is relatively calm, with a focus on fundamental analysis rather than speculative trading [11].